Thomas Cannell, Sesen Bio CEO
Sesen Bio pushes back after investor group attacks merger as ‘illogical’
Sesen Bio is pushing back against claims by a group of investors who control 8.4% of the company’s shares and who oppose a planned reverse …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
